KRP 104

Drug Profile

KRP 104

Alternative Names: KRP-104

Latest Information Update: 20 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ActivX Biosciences; Kyorin Pharmaceutical
  • Developer Kyorin Pharmaceutical
  • Class Antihyperglycaemics
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 04 Feb 2011 ActivX and Kyorin complete the Synergy 104 trial in Type-2 diabetes mellitus (NCT00995345)
  • 20 Aug 2008 Efficacy data from a phase IIa trial in Type 2 diabetes mellitus released by Kyorin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top